Our new cancer drug targets and disrupts chemo-resistant cells, reducing their capacity to grow and spread
We are developing a targeted adjunct therapy aimed at tackling chemo-resistant cells in aggressive cancers, including glioblastoma, breast, colon, lung, and pancreatic cancers. Our approach enhances existing treatments by disrupting the resilience of these hard-to-treat cancer cells, preventing relapse, and improving patient outcomes across a range of challenging cancers.
How we aim to revolutionize cancer treatments and prevent tumor recurrence
Leveraging the scientific creativity and expertise of our team and partners, we are set to redefine the fight against cancer. Our is a dynamic blend of biotech entrepreneurs, distinguished scientific leaders, pharmaceutical experts, and clinicians. United by a shared mission, we are dedicated to advancing oncology science and transforming patient outcomes worldwide.
We aim to revolutionize cancer treatments
Leveraging the scientific creativity and expertise of our team and partners, we are uniquely positioned to redefine the fight against cancer. Our team is a dynamic blend of experienced biotech entrepreneurs, scientific leaders, pharmaceutical experts, and clinicians. United by a shared mission, we are dedicated to advancing oncology science and transforming patient outcomes worldwide.